Wolfgang Pricken retweeted
New Bioadaptor evidence presented at TCT 2026.
Over the weekend, @DavidErlinge presented a patient-level pooled analysis of the INFINITY-SWEDEHEART and BIOADAPTOR RCT randomized controlled trials, examining two-year clinical outcomes following PCI with the DynamX® bioadaptor compared with contemporary DES.
The pooled analysis from bioadaptor trials provide the continued randomized evidence to date supporting restoration of vessel function as a novel therapeutic strategy for improving long-term outcomes after PCI.
•From 6 to 24 months, bioadaptor demonstrated superiority over DES indicating sustained clinical advantage after the early healing period
•Through two years, bioadaptor significantly reduced TLF, with greater treatment benefit observed in clinically important ACS and LAD populations which are at elevated risk of recurrent ischemic events
Explore the presentation and more from Elixir Medical at TCT 2026: elixirmedical.com/wp-content…
#TCT2026 #ElixirMedical #Bioadaptor #DynamX #PCI #ClinicalEvidence #InterventionalCardiology
The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.
Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.
Wolfgang Pricken retweeted
Elixir Medical is live at TCT 2026!
Stop by Booth #4319 to meet our team and learn more about the DynamX® Coronary Bioadaptor System and LithiX™ Hertz Contact Intravascular Lithotripsy.
And while you’re there, enjoy something special this year. Stop by and get an Elixir popcorn bag to snack on while you make your way around the show! 🍿
There’s plenty happening beyond the booth, too. Clinical data, scientific presentations, and our featured symposium are taking place throughout the meeting.
See what’s ahead and plan your TCT schedule: elixirmedical.com/ous/tct-20…
#TCT2026 #ElixirMedical #DynamX #LithiX #PCI #InterventionalCardiology
PMN 3035 Rev A
Wolfgang Pricken retweeted
💡 Studien kompakt: Dieses Mal geht es u.a. um eine Metaanalyse zur verkürzten DAPT, die Polypill-Strategie bei HFrEF, linksventrikuläre Erholung unter LVAD-Unterstützung sowie Mikroplastik im Koronarblut. Details zu den Studien:
➡️ herzmedizin.de/fuer-aerzte-u…
#Herzmedizinde #DGK #Kardiolgie
If restenosis were a person, it would now be rightfully worried about its existence 🎸💫 @AGIKinterv @YoungDgk @DGK_org
Today at #EuroPCR 2025, researchers presented the 3-year outcomes from the BIOADAPTOR-RCT, offering confirmation of the durability of the treatment—with sustained significantly lower TLF rates with the DynamX® Coronary Bioadaptor System compared to third-generation DES.
Dr. Shigeru Saito shared data showing lower TLF rates (2.7% vs. 7.2%) at 3 years follow-up.
The results also highlighted the continued separation of MACE event curves, supporting the role of bioadaptor technology in restoring vessel physiology and improving patient outcomes over time.
These findings mark an important milestone in coronary intervention.
#DynamX #Bioadaptor #ClinicalData #Medtech #Cardiology #RCT
5
144
Today at #EuroPCR 2025, researchers presented the 3-year outcomes from the BIOADAPTOR-RCT, offering confirmation of the durability of the treatment—with sustained significantly lower TLF rates with the DynamX® Coronary Bioadaptor System compared to third-generation DES.
Dr. Shigeru Saito shared data showing lower TLF rates (2.7% vs. 7.2%) at 3 years follow-up.
The results also highlighted the continued separation of MACE event curves, supporting the role of bioadaptor technology in restoring vessel physiology and improving patient outcomes over time.
These findings mark an important milestone in coronary intervention.
#DynamX #Bioadaptor #ClinicalData #Medtech #Cardiology #RCT
2
36
We’re excited to join the global interventional cardiovascular community in Paris for #EuroPCR2025, taking place May 20–23.
Elixir Medical technologies will be featured in several sessions, including presentations of new clinical data results, and will host two symposia covering the significant new clinical insights including:
3-year outcomes from the #BIOADAPTOR RCT
• Real-world evidence on #DynamX performance
• 24-month results from the DESyne BDS Plus RCT
• Highlights of recent cases using LithiX Hertz Contact #lithotripsy (#IVL)
We’re proud to be a leader in ongoing PCI innovation. Check out the full agenda and schedule for sessions and symposia.
#Medtech #Cardiology #Innovation #Bioadaptor #Lithotripsy
1
30
DynamX is rocking the world 🎸. Hear from the experts in #Mannheim why DynamX will also transform Cardiology in Germany - sooner or later. Save the Date:
Wednesday, April 23, 2025, at 5:30 p.m. in Hall 19
Join us, in person or online. As a special treat, we'll be showcasing the latest developments from LithiX, a simple yet ingenious approach to intravascular lithotripsy. #PerfectPCI @AGIKinterv @mirvatalasnag @Kardiophil @Hannah_Billig_ @HolgerNef @NikosWerner @doc_cardio @KardiologieHH @thiele_holger @DGK_org
Amazing launch of DynamX™ Bioadaptor in Egypt with @AlhyattGroup Heart & Vascular Center led by Dr. @hazemwarda! 3-day workshop including live lecture by Dr. @Antocol17 & 10 successful cases – 1st DynamX cases in Egypt & all of Africa!
#DynamX #Alhyatt #CardioTwitter
DynamX is rocking the world 🎸. Hear from the experts in #Mannheim why DynamX will also transform Cardiology in Germany - sooner or later. Save the Date:
Wednesday, April 23, 2025, at 5:30 p.m. in Hall 19
Join us, in person or online. As a special treat, we'll be showcasing the latest developments from LithiX, a simple yet ingenious approach to intravascular lithotripsy. #PerfectPCI @AGIKinterv @mirvatalasnag @Kardiophil @Hannah_Billig_ @HolgerNef @NikosWerner @doc_cardio @KardiologieHH @thiele_holger @DGK_org
46
Wolfgang Pricken retweeted
Attending #CRT2025?
Join us today at 11:30am in the Spotlight Theater for the Spotlight Session on bioadaptive angioplasty.
Faculty: Ron Waksman, David Erlinge, Shigeru Saito, Dean Kereiakes, MD, FACC, MSCAI, Mirvat Alasnag, Tamil Selvan Muthusamy, Pier Pasquale Leone
#DynamX
Always worth a read 👍
The eagerly awaited 2025 ACC/AHA ACS guidelines were released yesterday! Congrats to @SVRaoMD @DrM_ODonoghue and all the co-authors
1/ Here are some of my takeways
22
Legend ✨
Thanks @Hragy for posting this from the recent @IMCLIVEcongress. Here's the full clip of Andreas Gruentzig discussing "Complications" from my interview with him in 1985, just weeks before his untimely death. #AngioHistory
2
32
Wolfgang Pricken retweeted
Ich fahre an den ganzen Wahlplakaten der Ampel vorbei und denke mir: ernsthaft?
Mir absolut unerklärlich, wie Menschen das noch glauben können.
Great Initiative.
🚨 New #ESCCardioTalk episode alert! 🚨
This week, Shinwan Kany & @shaan_khurshid explore another piece in the atrial fibrillation puzzle! 🧩💡
From clinical insights to genetic risk and AI-powered ECG analysis, this episode covers it all! Don’t miss out on the latest in heart health innovation. 💥❤️
🎙️ Listen now bit.ly/3P42lJ6
#EHJ #CVD
28
Wolfgang Pricken retweeted
🔥 Save the Date! 🔥
#AGIK Women lädt am 07.–08.11 nach Düsseldorf ein: Herzklappenvitium – was dann?
Spannendes Thema mit führenden Expertinnen: Prof. Dr. @tk_rudolph, PD Dr. @GaedeLuise und PD Dr. Maike Knorr.
Sei dabei: akademie.dgk.org/anmeldung/p…
Wolfgang Pricken retweeted
Bench data for DCB
1️⃣Trackability of DCB
2️⃣particle release
3️⃣drug release
measured by @AlperOener. 👌👍
#DGKHerztage
#innovation
@Steph_Achenbach @mmamas1973 @KardiologieHH @dscharpfMD @mirvatalasnag @MarcVorpahl @thiele_holger @DrCathaHamm
Another technical Inspiration from Elixir Medical for the #PerfectPCI. Please get familiar with it. @AGIKinterv
Dive into this two-part series on Hertz Contact Intravascular Lithotripsy and the PINNACLE I study with Dr @valeriaparadies, Dr @mirvatalasnag and Dr Stefan Verheye 🔗Stream now 👉 ow.ly/O42v50TkPCx
📊 Part 1: Uncover the Hertz Contact technology and PINNACLE I findings
🥼 Part 2: Explore clinical endpoints, results and practice impacts
#PINNACLEIStudy #Cardiology #ClinicalTrials #CardioTwitter
3
92
#BioadaptiveAngioplasty #PerfectPCI Please pay attention to the Plateau 🙏💪
🚨INFINITY-SWEDEHEART: #DynamX® Bioadaptor meets primary endpoint and significantly reduces adverse events vs. DES after six months!
Full data: businesswire.com/news/home/2…
CE marked. Not for sale in the U.S.
#cardiotwitter #ESC2024
PMN 2001 REV A
1
24
If you are in London for the ESC 2024, please do not miss this one #PerfectPCI #BeyondDES @AGIKinterv @DGK_org
At #ESC2024, we’ll unveil late-breaking, 12-month primary outcomes from the 2,400-patient INFINITY-SWEDEHEART RCT evaluating #DynamX compared to contemporary DES. Read more: bwnews.pr/3X19EWL
@DavidErlinge
@stjam367
CE marked. Not for sale in the U.S.
PMN 1894 REV A
35























